JaLCDOI 10.18926/AMO/56080
フルテキストURL 72_3_319.pdf
著者 Makimoto, Go| Ichihara, Eiki| Hotta, Katsuyuki| Ninomiya, Kiichiro| Oze, Isao| Minami, Daisuke| Ninomiya, Takashi| Kubo, Toshio| Ohashi, Kadoaki| Tabata, Masahiro| Maeda, Yoshinobu| Kiura, Katsuyuki|
抄録 Although cisplatin-based chemotherapy shows a survival advantage compared to carboplatin for treating advanced non-small cell lung cancer, high-volume hydration and a long infusion time are necessary to avoid nephrotoxicity, and cisplatin-based chemotherapy has been difficult to administer in outpatient settings. A low-volume hydration method using mannitol or furosemide as forced diuresis was recently introduced, but there are no clear conclusions regarding which agent should be used. We describe our ongoing randomized phase II trial (the OLCSG1406 Study) evaluating the efficacy of forced diuresis. This study will clarify whether mannitol or furosemide is more suitable in cisplatin-based chemotherapy with low-volume hydration.
キーワード cisplatin mannitol furosemide lung cancer hydration non-small cell lung cancer
Amo Type Clinical Study Protocol
発行日 2018-06
出版物タイトル Acta Medica Okayama
72巻
3号
出版者 Okayama University Medical School
開始ページ 319
終了ページ 323
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2018 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 29926012